{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T02:07:09Z","timestamp":1789092429862,"version":"build-2803163510"},"reference-count":22,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2025,2,25]],"date-time":"2025-02-25T00:00:00Z","timestamp":1740441600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,2,25]],"date-time":"2025-02-25T00:00:00Z","timestamp":1740441600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100007195","name":"Universit\u00e0 degli Studi di Napoli Federico II","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100007195","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Nucl Med Mol Imaging"],"published-print":{"date-parts":[[2025,7]]},"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:sec>\n            <jats:title>Purpose<\/jats:title>\n            <jats:p>We performed an external validation of a predictive model for persistent\/metastatic disease in patients with differentiated thyroid cancer (DTC) at post-treatment <jats:sup>131<\/jats:sup>I whole-body scintigraphy (WBS).<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods<\/jats:title>\n            <jats:p>Our study population included 836 patients (median age 44\u00a0years, 78% women) with DTC referred from 1994 to 2021 at our center. Age, sex, histology, T stage, N stage, American Thyroid Association risk classes, thyroid-stimulating hormone, radioactive iodine (RAI) activity, and thyroglobulin (Tg) levels were considered potential predictors of post-treatment WBS results. For the external validation, N stage and Tg levels were put into the decision tree (DT) model using its same Tg cut-off values.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results<\/jats:title>\n            <jats:p>Ninety-nine patients (12%) had positive post-treatment WBS. The area under receiver operating characteristic (ROC) curve for predicting WBS findings through the external validation was 0.60 (95% confidence interval, CI, 0.56\u20130.64), and positive and negative predictive values were 58% (95% CI, 41\u201374%) and 90% (95% CI, 88\u201392%). We also developed an internal model including the independent predictors of WBS findings (i.e., Tg levels, T stage, N stage, and RAI activity). For this model the area under ROC curve was 0.75 (95% CI, 0.69\u20130.81), and positive and negative predictive values were 90% (95% CI, 68\u201399% and 88\u201392%).<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusions<\/jats:title>\n            <jats:p>The external validation of the proposed DT model has a limited value for predicting post-treatment <jats:sup>131<\/jats:sup>I-WBS findings in our patients. The internal model including also T stage and RAI activity demonstrates higher predictive value.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1007\/s00259-025-07124-2","type":"journal-article","created":{"date-parts":[[2025,2,25]],"date-time":"2025-02-25T03:21:06Z","timestamp":1740453666000},"page":"2867-2874","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["External validation of a predictive model for post-treatment persistent disease by 131I whole-body scintigraphy in patients with differentiated thyroid cancer"],"prefix":"10.1007","volume":"52","author":[{"given":"Carmela","family":"Nappi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rosario","family":"Megna","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emilia","family":"Zampella","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fabio","family":"Volpe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leandra","family":"Piscopo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Falzarano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlo","family":"Vallone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leonardo","family":"Pace","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mario","family":"Petretta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alberto","family":"Cuocolo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michele","family":"Klain","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,2,25]]},"reference":[{"key":"7124_CR1","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1016\/j.ando.2023.11.007","volume":"85","author":"P Raymond","year":"2024","unstructured":"Raymond P, Klein M, Borson-Chazot F. Summary and update on the management of differentiated thyroid cancer in 2023. Ann Endocrinol (Paris). 2024;85:110\u20137.","journal-title":"Ann Endocrinol (Paris)"},{"key":"7124_CR2","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1089\/thy.2015.0020","volume":"26","author":"BR Haugen","year":"2016","unstructured":"Haugen BR, Alexander EK, Bible KC, Doherty GM, Mandel SJ, Nikiforov YE, et al. 2015 American Thyroid Association Management Guidelines for adult patients with thyroid nodules and differentiated thyroid cancer: the American Thyroid Association Guidelines task force on thyroid nodules and differentiated thyroid cancer. Thyroid. 2016;26:1\u2013133.","journal-title":"Thyroid"},{"key":"7124_CR3","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1089\/thy.2022.0353","volume":"33","author":"A Wilhelm","year":"2023","unstructured":"Wilhelm A, Conroy PC, Calthorpe L, Shui AM, Kitahara CM, Roman SA, et al. Disease-specific survival trends for patients presenting with differentiated thyroid cancer and distant metastases in the United States, 1992\u20132018. Thyroid. 2023;33:63\u201373.","journal-title":"Thyroid"},{"key":"7124_CR4","doi-asserted-by":"publisher","first-page":"4437","DOI":"10.1007\/s00259-021-05440-x","volume":"48","author":"M Klain","year":"2021","unstructured":"Klain M, Nappi C, Zampella E, Cantoni V, Green R, Piscopo L, et al. Ablation rate after radioactive iodine therapy in patients with differentiated thyroid cancer at intermediate or high risk of recurrence: a systematic review and a meta-analysis. Eur J Nucl Med Mol Imaging. 2021;48:4437\u201344.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"7124_CR5","doi-asserted-by":"publisher","first-page":"923","DOI":"10.1056\/NEJMoa2111953","volume":"386","author":"S Leboulleux","year":"2022","unstructured":"Leboulleux S, Bournaud C, Chougnet CN, Zerdoud S, Al Ghuzlan A, Catargi B, et al. Thyroidectomy without radioiodine in patients with low-risk thyroid cancer. N Engl J Med. 2022;386:923\u201332.","journal-title":"N Engl J Med"},{"key":"7124_CR6","doi-asserted-by":"publisher","first-page":"312","DOI":"10.1089\/thy.2022.0542","volume":"33","author":"LB Walter","year":"2023","unstructured":"Walter LB, Scheffel RS, Zanella AB, Farenzena M, Faccin CS, Graudenz MS, et al. Active surveillance of differentiated thyroid cancer metastatic cervical lymph nodes: a retrospective single-center cohort study. Thyroid. 2023;33:312\u201320.","journal-title":"Thyroid"},{"key":"7124_CR7","doi-asserted-by":"publisher","DOI":"10.1200\/EDBK_389708","volume":"43","author":"S Agosto Salgado","year":"2023","unstructured":"Agosto Salgado S, Kaye ER, Sargi Z, Chung CH, Papaleontiou M. Management of advanced thyroid cancer: overview, advances, and opportunities. Am Soc Clin Oncol Educ Book. 2023;43: e389708.","journal-title":"Am Soc Clin Oncol Educ Book"},{"key":"7124_CR8","doi-asserted-by":"publisher","first-page":"2767","DOI":"10.1007\/s00259-023-06239-8","volume":"50","author":"L Giovanella","year":"2023","unstructured":"Giovanella L, Milan L, Roll W, Weber M, Schenke S, Kreissl M, et al. Postoperative thyroglobulin as a yard-stick for radioiodine therapy: decision tree analysis in a European multicenter series of 1317 patients with differentiated thyroid cancer. Eur J Nucl Med Mol Imaging. 2023;50:2767\u201374.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"7124_CR9","doi-asserted-by":"publisher","first-page":"3066","DOI":"10.1007\/s00259-020-04938-0","volume":"47","author":"M Klain","year":"2020","unstructured":"Klain M, Nappi C, Nicolai E, Romeo V, Piscopo L, Giordano A, et al. Comparison of simultaneous 18F-2-[18F] FDG PET\/MR and PET\/CT in the follow-up of patients with differentiated thyroid cancer. Eur J Nucl Med Mol Imaging. 2020;47:3066\u201373.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"7124_CR10","doi-asserted-by":"publisher","first-page":"1740","DOI":"10.3390\/diagnostics11101740","volume":"11","author":"M Klain","year":"2021","unstructured":"Klain M, Nappi C, De Risi M, Piscopo L, Volpe F, Manganelli M, et al. Whole-body radioiodine effective half-life in patients with differentiated thyroid cancer. Diagnostics (Basel). 2021;11:1740.","journal-title":"Diagnostics (Basel)"},{"key":"7124_CR11","doi-asserted-by":"crossref","first-page":"15N","DOI":"10.2967\/jnumed.121.262402","volume":"63","author":"AM Avram","year":"2022","unstructured":"Avram AM, Giovanella L, Greenspan B, Lawson SA, Luster M, Van Nostrand D, et al. SNMMI procedure standard\/EANM practice guideline for nuclear medicine evaluation and therapy of differentiated thyroid cancer: abbreviated version. J Nucl Med. 2022;63:15N-35N.","journal-title":"J Nucl Med"},{"issue":"12","key":"7124_CR12","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0169341","volume":"2017","author":"T Ohnuma","year":"2017","unstructured":"Ohnuma T, Uchino S. Prediction models and their external validation studies for mortality of patients with acute kidney injury: a systematic review. PLoS ONE. 2017;2017(12): e0169341.","journal-title":"PLoS ONE"},{"key":"7124_CR13","doi-asserted-by":"publisher","first-page":"1007","DOI":"10.1007\/s00420-020-01548-z","volume":"93","author":"MFA van Hoffen","year":"2020","unstructured":"van Hoffen MFA, Norder G, Twisk JWR, Roelen CAM. External validation of a prediction model and decision tree for sickness absence due to mental disorders. Int Arch Occup Environ Health. 2020;93:1007\u201312.","journal-title":"Int Arch Occup Environ Health"},{"key":"7124_CR14","doi-asserted-by":"publisher","first-page":"2967","DOI":"10.1007\/s12350-021-02855-9","volume":"29","author":"R Megna","year":"2022","unstructured":"Megna R, Petretta M, Assante R, Zampella E, Nappi C, Gaudieri V, et al. External validation of the CRAX2MACE model in an Italian cohort of patients with suspected coronary artery disease undergoing stress myocardial perfusion imaging. J Nucl Cardiol. 2022;29:2967\u201373.","journal-title":"J Nucl Cardiol"},{"key":"7124_CR15","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1177\/13524585221136036","volume":"29","author":"N Moradi","year":"2023","unstructured":"Moradi N, Sharmin S, Malpas CB, Shaygannejad V, Terzi M, Boz C, et al. External validation of a clinical prediction model in multiple sclerosis. Mult Scler. 2023;29:261\u20139.","journal-title":"Mult Scler"},{"key":"7124_CR16","doi-asserted-by":"publisher","first-page":"1443","DOI":"10.1007\/s12350-022-03173-4","volume":"30","author":"M Petretta","year":"2023","unstructured":"Petretta M, Megna R, Assante R, Zampella E, Nappi C, Gaudieri V, et al. External validation and update of the J-ACCESS model in an Italian cohort of patients undergoing stress myocardial perfusion imaging. J Nucl Cardiol. 2023;30:1443\u201353.","journal-title":"J Nucl Cardiol"},{"key":"7124_CR17","doi-asserted-by":"publisher","first-page":"803","DOI":"10.1007\/s00259-023-06540-6","volume":"51","author":"FM Sasaki","year":"2024","unstructured":"Sasaki FM, Leal ALG, de Almeida Filho PJ, Mourato FA. Letter to the Editor: Postoperative thyroglobulin as a yard-stick for radioiodine therapy: decision tree analysis in a European multicenter series of 1317 patients with differentiated thyroid cancer. Eur J Nucl Med Mol Imaging. 2024;51:803\u20134.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"7124_CR18","doi-asserted-by":"publisher","first-page":"488","DOI":"10.1053\/j.semnuclmed.2024.05.002","volume":"54","author":"NC Nguyen","year":"2024","unstructured":"Nguyen NC, Anigati EM, Desai NB, \u00d6z OK. Radioactive iodine therapy in differentiated thyroid cancer: an update on dose recommendations and risk of secondary primary malignancies. Semin Nucl Med. 2024;54:488\u201396.","journal-title":"Semin Nucl Med"},{"key":"7124_CR19","doi-asserted-by":"publisher","first-page":"717","DOI":"10.2967\/jnumed.116.179606","volume":"58","author":"D Deandreis","year":"2017","unstructured":"Deandreis D, Rubino C, Tala H, Leboulleux S, Terroir M, Baudin E, et al. Comparison of empiric versus whole-body\/-blood clearance dosimetry-based approach to radioactive iodine treatment in patients with metastases from differentiated thyroid cancer. J Nucl Med. 2017;58:717\u201322.","journal-title":"J Nucl Med"},{"key":"7124_CR20","doi-asserted-by":"publisher","first-page":"3225","DOI":"10.1007\/s00259-023-06295-0","volume":"50","author":"J Taprogge","year":"2023","unstructured":"Taprogge J, Vergara-Gil A, Leek F, Abreu C, V\u00e1vrov\u00e1 L, Carnegie-Peake L, et al. Normal organ dosimetry for thyroid cancer patients treated with radioiodine as part of the multi-centre multi-national Horizon 2020 MEDIRAD project. Eur J Nucl Med Mol Imaging. 2023;50:3225\u201334.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"7124_CR21","doi-asserted-by":"publisher","first-page":"4087","DOI":"10.1210\/jc.2019-00177","volume":"104","author":"RM Tuttle","year":"2019","unstructured":"Tuttle RM, Alzahrani AS. Risk Stratification in differentiated thyroid cancer: from detection to final follow-up. J Clin Endocrinol Metab. 2019;104:4087\u2013100.","journal-title":"J Clin Endocrinol Metab"},{"key":"7124_CR22","doi-asserted-by":"crossref","unstructured":"Harrell FE Jr. Regression modeling strategies. With applications to linear models, logistic and ordinal\u00a0regression, and survival analysis. 2nd ed. Springer Series in Statistics; 2015;18.","DOI":"10.1007\/978-3-319-19425-7"}],"container-title":["European Journal of Nuclear Medicine and Molecular Imaging"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00259-025-07124-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00259-025-07124-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00259-025-07124-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,12]],"date-time":"2025-06-12T05:23:10Z","timestamp":1749705790000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00259-025-07124-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2,25]]},"references-count":22,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2025,7]]}},"alternative-id":["7124"],"URL":"https:\/\/doi.org\/10.1007\/s00259-025-07124-2","relation":{},"ISSN":["1619-7070","1619-7089"],"issn-type":[{"value":"1619-7070","type":"print"},{"value":"1619-7089","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,2,25]]},"assertion":[{"value":"23 September 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 January 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 February 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This is an observational study. The Ethics Committee Campania 3 has confirmed that no ethical approval is required and informed consent was waived.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Alberto Cuocolo declared the following conflict of interest: European Journal of Nuclear Medicine and Molecular Imaging, Associate Editor.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}